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Background. The number of patients of all age brackets diagnosed with Inflammatory Bowel Disease (IBD) has risen dramatically
worldwide over the past 50 years. IBD’s changing epidemiology suggests that environmental factors play a major role in modifying
disease expression. Aim. To review studies carried out worldwide analyzing IBD epidemiology. Methods. A Medline search
indicating as keywords “Inflammatory Bowel Disease,” “epidemiology,” “natural history,” “Crohn’s Disease,” “Ulcerative Colitis,”
and “IBD Unclassified” was performed. A selection of clinical cohort and systematic review studies that were carried out between
2002 and 2013 was reviewed. Studies referring to an earlier date were also considered whenever the data were relevant to our
review. Results. The current mean prevalence of IBD in the total population of Western countries is estimated at 1/1,000. The
highest prevalence and incidence rates of IBD worldwide are reported from Canada. Just as urbanization and socioeconomic
development, the incidence of IBD is rising in China. Conclusions. Multicenter national registers and international networks can
provide information on IBD epidemiology and lead to hypotheses about its causes and possible management strategies. The rising
trend in the disease’s incidence in developing nations suggests that its epidemiological evolution is linked to industrialization and
modern Westernized lifestyles.
1. Introduction
The number of patients of all age brackets diagnosed
with Inflammatory Bowel Disease (IBD) has dramatically
increased worldwide over the past 50 years. The changing
epidemiology of IBD across time and geography suggests
that environmental factors are involved in modifying disease
expression [1]. Insight into the worldwide epidemiology
of this disease is, thus, important to identify geographic
patterns and time trends. Recent findings will also make it
possible to estimate the global public health burden so that
health care resources can be allocated and research can be
targeted in specific geographic regions. Information about
environmental factors hypothetically affecting the incidence
and prevalence of this disease may, finally, lead to prevention
interventions when possible.
The aim of this paper is to review the current levels of
knowledge concerning IBD epidemiology worldwide and to
examine its natural history in paediatric patients.
The first paragraphs of Section 3 of this report will
provide an overview of statistics concerning the incidence
and prevalence in the general and paediatric worldwide
population, considering its two forms, Crohn’s Disease (CD)
and Ulcerative Colitis (UC) separately.The rest of the section
will outline disease trends in specific geographic areas. In
Section 4, we will go on to describe the disease’s natural
history in the paediatric population examining, as before, the
two forms separately.
2. Methods
A Medline search using the following keywords “Inflam-
matory Bowel Disease,” “epidemiology,” “natural history,”
“Crohn’s Disease,” “Ulcerative Colitis,” and “Unclassified
IBD” was carried out.
Clinical cohort and systematic review studies performed
during the 2002–2013 time frame were reviewed. Studies
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conducted earlier were also taken into consideration when-
ever the data outline was considered relevant to this review.
In view of the fact that they are characteristically based on
homogeneous diagnostic criteria, practical aspects of pheno-
typic data collection, and clinical expertise on IBD treatment,
population-based studies were given priority in the selection
process. Studies based on health administrative databases
were also included whenever they clarified epidemiology
statistics in particular with reference to paediatric patients
[2].
3. IBD Epidemiology Worldwide: Data
Regarding the General and Paediatric
Populations
The etiology of IBDs, which are disorders of chronic inflam-
mation of the gastrointestinal tract marked by episodes of
relapse and remission, is not yet fully elucidated. Its two
main forms, CD and UC, are diagnosed on the basis of a
clinical suspicion and laboratory, radiological, endoscopic,
and histological findings [22]. It is not always possible to
distinguish between these two forms using the diagnostic
tools available, and the term Inflammatory Bowel Disease
Unclassified (IBD-U) is currently used to categorise this
subgroup of patients with chronic intestinal inflammation. It
is important to remember that the misclassification and/or
reclassification of the disease can cause diagnostic delays
as well as underestimation of IBD’s global prevalence and
incidence [23, 24].
The reasons behind the rising worldwide trend are not
entirely clear [1]. The current mean prevalence of IBD in
the general population of Western countries is estimated at
1/1,000 inhabitants [25, 26]. Although there are only few
epidemiologic data available regarding developing countries,
the disease’s incidence and prevalence seem to be increasing
over the past 50 years in practically all regions of the world,
indicating its emergence as a global disease [27, 28].The trend
appears to have stabilised for the adult population but not for
the paediatric one, especially in Central and Southern Europe
where it appears to be rising [29, 30].
Both forms of the disease are thought to be linked to
a combination of individual genetic susceptibility, environ-
mental triggers, and alterations in the gut microbiome that
stimulate an inflammatory response. The changing epidemi-
ology of IBD across time and geographic areas suggests that
environmental factors play a major role in modifying disease
expression, and its rising incidence in developing nations
seems to be linked to industrialization and the Western
lifestyle. The most important environmental associations
that have been identified until now are cigarette smoking
and appendectomy, although neither alone can explain the
variation in the incidence of IBD worldwide. Urbanization in
some developing countries, diet changes, antibiotics, hygiene
status, microbial exposure, and pollution have all been
implicated as potential environmental risk factors for IBD,
and individual, familial, and community-, regional-, and
country-based environmental risk factors could, singularly or
together, contribute to its pathogenesis [31].
Estimates of the incidence of paediatric-onset IBD
reported around the world vary considerably [24] as do its
patterns and distributions in the various age brackets of the
paediatric population [32, 33]. Although less prevalent in
infants and in very young children, a number of case reports
and small population studies have documented disease onset
at very early ages. Heyman et al. [34] analyzed the data from a
largemulticenter registry of children and adolescents affected
by IBD in the attempt to answer specific epidemiologic
questions. The cohort—58% diagnosed with CD, 29% with
UC, and 13% with IBD-U—contained both incident and
prevalent cases enrolled over a 2-year period. According to
multivariate analysis, the children younger than 8 were 2.5
times more likely to have UC and 3.5 times more likely to
have IBD-U than those older than 8. Colonic involvement
with or without disease at other sites was more prevalent
in the younger patients. Patients with early-onset IBD, in
particular very young patients with UC, were more likely to
report a family history of IBD. Patients with familial forms
(i.e., children whose parents also suffer from IBD) generally
develop the disease earlier due to the genetic anticipation
phenomenon [35].
Very early IBD onset appears to distinguish a subgroup
of patients with unique characteristics [36–38]. Underlying
immune deficiencies including glycogenosis, IL-10R defi-
ciency, and other mutations involving cytokines, receptors,
or mediators must always be excluded when a child under
5 is being diagnosed. An intestinal IBD-like pattern has
been found to be associated in these cases with systemic
immunodeficiency within a complex scenario which can
even lead to severe life-threatening events (i.e., systemic
infections) [39, 40].
Glocker et al. [41] identified mutations in genes encoding
the IL10R subunit proteins in patients with early-onset ente-
rocolitis, involving hyperinflammatory immune responses in
the intestine. Genetic-linkage analysis and candidate-gene
sequencing on samples from two unrelated consanguineous
families with children affected by early-onset IBD and
functional assays of patients’ peripheral blood mononuclear
cells were carried out. The investigators identified three
distinct homozygousmutations in genes IL10RA and IL10RB,
encoding the IL10R1 and IL10R2 proteins in four out of
nine patients with early-onset colitis.Themutations abrogate
interleukin-10-induced signalling. According to some case
studies examining IL-10R deficient patients, hematopoietic
stem cell transplantation (HSCT) is generally successful [40–
42].
Assessing the incidence of IBD is complicated, especially
in the developmental age, as epidemiological investigations
tend to ignore cases of IBD-U although they are generally
considered an early stage of the disease (in up to 13% of
cases and in as much as up to 20% in some Northern
European populations) [29, 30, 43]. IBD can also be difficult
to recognize, particularly in children when these present
atypical symptoms and in third world countries where med-
ical services are lacking.
3.1.TheWorldwide Incidence of UC and CD in the General and
Paediatric Populations. The incidence of UC has been rising
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in Western countries over the past 50 years, incrementing
from 8–14/100,000 to 120–200/100,000 persons over that
period [44]. Moreover, research on migrant populations and
persons living in developing countries has reported a recent,
gradual increase in the incidence of UC. The disease seems
to peak between 10 and 18 years and to affect both genders
equally [29, 43, 45].
The incidence of CD has also risen significantly over
that time period, incrementing from 6–15/100,000 to 50–
200/100,000 persons [44]. While initially relatively low, CD
incidence has gradually risen to levels that are similar to those
of UC [44]. While CD incidence rates seem to have stabilized
in most industrialized countries since the 1980s, an increase
in the childhood-onset form continues to be noted [3, 4]
(Table 1).
CD incidence seems to peak late in adolescence and in
young adulthood (up to 25 years of age). A second incidence
peak has been noted for both CD and UC at the sixth
or seventh decade [29, 43]. Moreover, a secondary peak is
reported in several paediatric cohorts in the preschool age
group (4-5 yrs of age) [29, 43, 46].
While CD appears to have a predilection for the female
sex in the population at large, male predominance has been
observed in the paediatric age bracket [29, 43, 45].
3.2.The Incidence and Prevalence of UC and CD in the General
and Paediatric Populations Specific to Geographic Areas. A
recent systematic review by Molodecky et al. [27] examined
data from 167 studies concerning Europe (1930–2008), 52
concerning Asia and the Middle East (1950–2008), and 27
concerning North America (1920–2004). The highest annual
incidence rate of UC—24.3 per 100,000 person-years—was
registered in Europe, followed at 19.2 per 100,000 person-
years registered in North America and then at 6.3 per 100,000
person-years noted in Asia and the Middle East. The highest
annual incidence of CD was, instead, registered in North
America at 20.2 per 100,000 person-years; it was followed
at 12.7 per 100,000 person-years by Europe and then at
5 per 100,000 person-years by Asia and the Middle East.
The highest reported prevalence values for IBD were found
in Europe (for UC, 505 per 100,000 persons; for CD, 322
per 100,000 persons) and North America (for UC, 249 per
100,000 persons; for CD, 319 per 100,000 persons) [27].
3.3. Europe. The incidence of IBD appears to be twice as high
in Western with respect to Eastern Europe [1], although an
increasing incidence has also been noted in the latter area.
A prospective, uniformly diagnosed population study by the
EpiComgroup [5] which analyzed the ECCO-EpiCom incep-
tion cohort of IBD patients was interested in investigating
a possible East-West gradient in the incidence of IBD in
Europe. A cohort of IBD patients attending 31 centers in 14
Western and 8 Eastern European countries providingmedical
services to a total population of approximately 10.1 million
peoplewas studied.Approximately 1500 patients aged 15 years
or older were included in the study population. The overall
incidence rate ratios in all theWestern European centers were
1.9 (95%CI 1.5 to 2.4) for CDand 2.1 (95%CI 1.8 to 2.6) forUC
compared with Eastern European centers. The median crude
annual incidence rates per 100,000 in 2010 for CD were 6.5
(range 0–10.7) in Western European centers and 3.1 (range
0.4–11.5) in Eastern ones; for UC it was 10.8 (range 2.9–31.5)
and 4.1 (range 2.4–10.3), respectively, and for IBD-U it was 1.9
(range 0–39.4) and 0 (range 0–1.2), respectively. The authors
concluded that there is indeed an East-West gradient in IBD
incidence in Europe [5] (Table 1).
According to the data from the EPIMAD Registry, col-
lected between 1988 and 2007 and referring to a large area of
Northern France populated by almost 6 million inhabitants
representing 9.3% of the entire French population [47], there
was an increase in CD incidence rates which rose from
5.2 cases/100,000 persons in 1988–1990 to 6.7 in 2006-2007
(+29%). The trend seemed to stabilize after a peak of 7.1 was
reached in 1997–1999. CD incidence rates in the 10–19-year-
old persons increased by 71% rising from 6.5 (1988–1990)
to 11.1 (2006-2007). UC incidence rates, instead, decreased
during that same period [47].
A sharp increase in paediatric (<16 years) IBD incidence
was reported by a Swedish study carried out in a north-
ern Stockholm County between 2002 and 2007 [6]. The
increasing incidence in IBD was primarily explained by the
rising incidence—registered at 9.2 (95% CI 7.5–11.2)—in CD
patients. UC incidence was found to be 2.8 (95% CI 1.9–4.0).
A significant increase in the incidence of UC (𝑃 < 0.05) but
not of CD was observed over the study period. The authors
concluded that CD continued to be predominant and there
was an increase in UC incidence during the study period [6]
(Table 1).
A study by Turunen et al. aimed to analyze the incidence
and the clinical picture of IBD from 1987 to 2003 in a large
paediatric population in Finland [7]. Data were collected
from patient discharge and medical records at the country’s
2 largest university hospitals. A total of 604 cases of IBD
were diagnosed during the 17-year study period: 203 (34%) of
these were registered as CD, 317 (52%) as UC, and 83 (14%)
as IBD-U. The mean annual incidence rate increased from
3.9/100,000 (95% confidence interval (CI) 2.5–5.8) in 1987 to
7.0/100,000 (CI 5.0–9.4) in 2003 (𝑃 < 0.001). The majority of
cases were patients who are 12 to<15 years old (𝑛 = 200, 33%);
5.1%were<3 years old, and 14%were<6 years old. IBD-Uwas
most common in young children (29% of all IBD-U patients).
Surgical procedures were generally carried out early during
disease course [7] (Table 1).
Another Finnish study carried out by Jussila et al. [4]
aimed to assess the geographic distribution of IBD in that
country and to estimate its nationwide incidence between
2000 and 2007. The register included all new cases of IBD
between 2000 and 2007 which received special reimburse-
ment for IBD medication. Overall, 14,214 IBD patients were
identified: 10,352 had UC and 3,862 CD. During the study
period the mean annual incidence of IBD per 100,000 was
34.0 : 9.2 in CD and 24.8 in UC. The incidence of UC was
notably higher in the males (27.8) than in the females (21.9).
In CD the incidence increased only slightly and rates did
not differ significantly between genders. The incidence of
UC increased from 22.1 in 2000-2001 to 27.4 in 2006-2007.
The authors concluded that the incidence of IBD is high in
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Table 1: Summary of the main studies on IBD epidemiology that were reviewed for the special issue.
Authors/paper/year
[Reference] Country
Number of IBD
patients enrolled Patients age
Time period of
the study IBD incidence
Benchimol et al., Gut
2009 [2] Canada (Ontario)
Population-based
clinical database
Paediatric
(<15 yrs) 17 yrs (1991–2008)
Age- and sex-standardized
prevalence 42.1/100,000 (in
1994)
56.3/100,000 (in 2005)
incidence
9.5/100,000 (in 1994)
11.4/100,000 (in 2005).
Chouraki et al.,
Aliment. Pharmacol.
Ther. 2011 [3]
Northern France
(EPIMAD Registry)
12.084
CD 7428
UC 4656
Paediatric 20 yrs(1988–2007)
CD
In 1988–1990: 5.2/100,000
In 2006-2007:
6.7/100,000
Jussila et al., J. Crohn’s
Colitis 2013 [4] Finland
Patients with special
reimbursement of
medications for IBD in
the years 1993 (𝑛 =
10,958) and 2008
(31,703)
Paediatric and
adult
14 yrs
(1998–2002)
Nationwide point prevalence
of IBD 216/100,000 in 1993
and 595/100,000 in 2008.
Burisch et al., Gut
2013. [5]
Europe (31 centers
from 14 Western and
8 Eastern European
countries)
1515 patients
535 (35%) CD
813 (54%) UC
167 (11%) IBD-U
Adult (≥15 yrs) —
Overall incidence rate ratios
in all Western European
centres were 1.9 (95% CI 1.5
to 2.4) for CD and 2.1 (95%
CI 1.8 to 2.6) for UC
compared with Eastern
European centres
Median crude annual
incidence rates per 100,000
in 2010:
CD 6.5 (range 0–10.7) in
Western European centres
3.1 (range 0.4–11.5) in
Eastern European centres
UC 10.8 (range 2.9–31.5) in
Western European centres
and 4.1 (range 2.4–10.3) in
Eastern European centres
IBDU 1.9 (range 0–39.4) in
Western European centres
and 0 (range 0–1.2) in
Eastern European centres
Malmborg et al., J.
Pediatr.
Gastroenterol. Nutr.
2013 [6]
Sweden
(Stockholm county) 133
Paediatric
(<16 yrs at onset) 6 yrs (2002–2007)
IBD
12.8/100,000 (95% CI
10.8–15.2)
CD
9.2 (95% CI 7.5–11.2)
UC
2.8 (95% CI 1.9–4.0)
Turunen et al.,
Inflamm. Bowel Dis.
2006 [7]
Finland
604
CD 203 (34%)
UC 317 (52%)
IBD-U 83 (14%)
Paediatric
(<18 yrs at onset)
12 to <15 yrs: 200
(33%)
<3 yrs: 5.1%
<6 yrs: 14%
17 yrs (1987–2003)
IBD
In 1987: 3.9/100,000 (95% CI
2.5–5.8)
In 2003:
7.0/100,000 (CI 5.0–9.4)
(𝑃 < 0.001)
Sawczenko and
Sandhu, Arch. Dis
Child 2003 [8]
Great Britain and
Ireland
739
CD 431
UC 211
IBD-U 86
Paediatric
(<16 yrs at onset)
13mths (June
1998–June 1999) —
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Table 1: Continued.
Authors/paper/year
[Reference] Country
Number of IBD
patients enrolled Patients age
Time period of
the study IBD incidence
Armitage et al.,
Gastroenterology
2004. [9]
Scotland 580 Paediatric(<16 yrs at onset) 15 yrs (1981–1995)
CD
2.3 (95% CI: 2.0–2.5)
(Northern Scotland 3.1, 95%
CI: 2.6–3.8; Southern
Scotland 2.1 95% CI: 1.9–2.4,
𝑃 < 0.001)
Pozler et al., J. Pediatr.
Gastroenterol. Nutr.
2006 [10]
Czech Republic 470CD 223
Paediatric
(<15 yrs at onset) 12 yrs (1990–2001)
CD
In 1990: 0.25/100,000, in
2001: 1.25/100,000
Castro et al., Inflamm
Bowel Dis 2008. [11] Italy
1576
UC 810
CD 635
IBD-U 131
Paediatric
(<18 yrs) 8 yrs (1996–2003)
IBD incidence:
0.39/100,000
(1996)–0.89/100,000 (2003)
Rocchi et al., Can. J.
Gastroenterol. 2012
[12]
Canada
233,000
CD 129,000
UC 104,000
(5900 children with
IBD)
Paediatric and
adult (<18 yrs at
onset)
12 yrs
(1998–2009)
IBD
Prevalence 0.67%
Incidence: 10,200 cases/yr
Zeng et al., J.
Gastroenterol.
Hepatol. 2013 [13]
China (Guangdong
province)
48
CD 17
UC 31
Paediatric and
adult 1 yr (2011-2012)
IBD 3.14/100,000
CD 1.09/100,000
UC 2.05/100,000
Kugathasan et al., J.
Paediatr. 2003 [14] Winsconsin, US — Paediatric 2 yrs
IBD
7.05/100,000
CD 4.56/100,000,
UC
2.14/100,000
Basu et al., Am J.
Gastroenterol. 2005
[15]
Houston, Texas, US
148
Whites 40%, African
Americans 37%,
Mexican Americans
20%, Asians 3%
Paediatric and
adult
4 yrs (June
1999–November
2003)
—
Tozun et al., J. Clin.
Gastroenterol 2009.
[16]
Turkey
877
CD 216
UC 661
Paediatric and
adult 3 yrs (2001–2003)
CD 2.2/100,000
UC 4.4/100,000
Abdul-Baki et al.
Inflamm Bowel Dis
2007 [17]
Lebanon
251
UC 142
CD 100
IBD-U 9
Paediatric and
adult 5 yrs (2000–2004)
CD 1.4/100,000
UC 4.1/100,000
(range, 0–6.9/100,000 for
both)
El Mouzan et al., J.
Trop. Pediatr. 2006
[18]
Saudi Arabia
(Riyadh region)
50
CD 38%
UC 48%
IBD-U 16%
Paediatric
(<18 yrs at onset)
<12 yrs: 16%
10 yrs
(1993–2002) 0.5 cases/100,000
Tsai et al., J. Formos.
Med. Assoc. 2004 [19] Taiwan
17
CD 9 (53%)
UC 6 (35%)
IBD-U 2 (12%)
Paediatric
(<18 yrs at onset)
22 yrs
(1979–2000)
CD
From 1979 to 1995: 0.85%
From 1996 to 2000: 2.6%
(𝑃 < 0.001),
UC
From 1979 to 1995: 0.85%
From 1996 to 2000: 0.99%
(𝑃 = 0.16)
Ng et al.,
Gastroenterology
2013 [20]
Asia-Pacific
(8 countries between
Asia and Australia)
419
CD 166
UC 232
IBD-U 21
Paediatric and
adult 1 yr (2011-2012)
Asia
IBD
1.37/100,000
(95% CI: 1.25–1.51)
CD 0.54
UC 0.76
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Table 1: Continued.
Authors/paper/year
[Reference] Country
Number of IBD
patients enrolled Patients age
Time period of
the study IBD incidence
IBD-U 0.07
China
3.44 per 100,000 individuals
Australia
IBD
23.67/100,000
(95% CI: 18.46–29.85)
CD 14
UC 7.33
IBD-U 2.33
Pinsk et al., Am. J.
Gastroenterol. 2007.
[21]
South Asian
population in British
Columbia, Canada
75
CD 48%
UC 33.3%
IBD-U 18.7%
Paediatric
(<16 yrs)
21 yrs
(1985–2005)
In 1996–2001:
IBD 15.19/100,000
CD 6.41/100,000, UC
6.70/100,000 IBD-U
2.08/100,000
IBD: Inflammatory Bowel Disease, CD: Crohn’s Disease, UC: Ulcerative Colitis, IBD-U: Unclassified IBD, yrs: years, CI: confidence interval.
FinlandwithUCbeing almost three timesmore frequentwith
respect to CD. The incidence rate of UC since the year 2000
has increased, while that of CD has remained fairly stable. A
North-South gradient was clearly identified for IBD and UC
but not for CD [4] (Table 1).
Sawczenko and Sandhu [8] prospectively described the
presenting features, disease localisation, and disease growth
in newly diagnosed cases of IBD in a multicenter study
conducted between June 1998 and June 1999 in the UK and
Ireland. A total of 739 new IBD cases of patients younger
than 16 were identified. Only one-quarter of the CD cases
presented with the “classic triad” of diarrhoea, weight loss,
and abdominal pain; nearly half did not report diarrhoea.
Themedian delay from onset of symptoms to diagnosis was 5
months (mean 11 months). Delays were more common in the
CD patients and in the younger children. Short stature was
noted only in the patients with CD and not in those with UC.
One-fifth of the CD cases had small bowel involvement and
also significantly reduced stature. Ileocolonic involvement
was documented in most of the CD cases, with only a small
minority having isolated ileal or isolated colonic disease.
Pancolitis was reported in most of the UC cases, with only
a very few affected with isolated proctitis [8] (Table 1).
A study by Armitage et al. [9] aimed to analyse the
sociodemographic and geographic distribution of paediatric-
onset CD in Scotland. Using a national database, 580 Scottish
children (<16 years of age at symptom onset) who were
diagnosed with IBD between 1981 and 1995 were identified.
The incidence of paediatric-onset CD was 2.5 cases per
100,000 population per year (95% CI: 2.0–2.5) for the 1981–
1995 time period and it was significantly higher in Northern
(3.1, 95% CI: 2.6–3.8) with respect to Southern Scotland (2.1,
95% CI: 1.9–2.4, 𝑃 < 0.001). The incidence of paediatric-
onset UC did not, instead, show any north/south variations
(𝑃 = 0.677). While children from more affluent areas had
a higher relative risk of developing CD, paediatric-onset UC
did not seem to be associated with affluence [9] (Table 1).
A study conducted in the Czech Republic [10] between
1990 and 2001 aimed to assess the paediatric population
suffering from IBD and to determine the incidence of CD
in children younger than 15 during the study period. The
diagnostic criteria were met by 470 IBD patients; 201 of these
turned 18 during the study period. CD was diagnosed in 223
patients.The incidence of CD in the patients younger than 15
rose from 0.25/100,000 in 1990 to 1.25/100,000 in 2001. Severe
growth retardation was recorded in 6.4% of the adolescents
with CD at the age of 18. UC was diagnosed in 202 patients.
The criteria for IBD-Uweremet in 9.8%of all the IBDpatients
[10] (Table 1).
A study was carried out by Italian investigators utilizing
the National Paediatric IBD Register which was instituted in
1996. The data analysed by the study were collected from the
time the register was instituted until 2003 [11]. According to
those data, IBDwas more frequent in children between 6 and
12 years (57%), although 20% developed their first symptoms
before the age of 6. In 1.8% of cases a diagnosis was made
within the first year of life. Diagnosis of IBD-U was more
frequent in children between 0 and 5 (more than twice as high
with respect to older children) and accounted for 10–15% of
all new diagnoses of IBD. Mean values of the time interval
between onset of symptoms and IBD diagnosis were 10.1
months for CD, 9 months for IBD-U, and 5.8 months for UC.
Extended colitis was the most frequent form in UC and ileo-
colic involvement the most frequent in CD. Upper intestinal
tract involvement was present in 11% of CD patients. IC
locations were similar to those of UC. Bloody diarrhea and
abdominal pain were themost frequent symptoms in UC and
IC, and abdominal pain and diarrhea in CD. Extraintestinal
symptoms were more frequent in CD than in UC (Table 1).
3.4. The Americas. Canada has one the highest prevalence
and incidence rates of IBD in the world [48]. A compre-
hensive review analysing the burden of IBD, its direct and
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indirect medical costs, and humanistic impact in Canada
was recently conducted by Rocchi et al. [12]. Approxi-
mately 233,000 Canadians were diagnosed with IBD by 2012
(129,000 with CD and 104,000 with UC), corresponding
to a prevalence of 0.67%. Approximately 10,200 new cases
are diagnosed annually. IBD is diagnosed at all ages, with
typical onset occurring in the second or third decades of life.
Compared to the general population, the quality of life of IBD
patients was low across all health dimensions and medical
costs associated to its care were high [12]. The review by
Rocchi et al. highlighted the elevated burden of the disease
in that country due to its high prevalence and medical costs.
The authors concluded that Canada is characterized by lack of
awareness of IBD as a chronic disease, late or inappropriate
diagnosis, inequitable access to health care services, costly
medication, diminished employment prospects, and limited
community-based support [12] (Table 1).
Benchimol et al. [2] used a population-based clinical
health administrative database of IBD patients younger than
15 years living in Ontario, Canada, to define paediatric-onset
IBD and to describe its epidemiology. The most accurate
algorithm was validated with chart data regarding children
from 12medical practices. Identification of children with IBD
required four physician contacts or two hospitalisations with
International Classification of Disease (ICD) codes for IBD
within 3 years’ time if they underwent colonoscopy and seven
contacts or three hospitalisations within 3 years’ time in those
without colonoscopy. Age- and sex-standardised prevalence
per 100,000 population of paediatric IBD increased from 42.1
(in 1994) to 56.3 (in 2005). Incidence per 100,000 increased
from 9.5 (in 1994) to 11.4 (in 2005). Statistically significant
increases in incidence were noted in 0–4-year-old persons
(5.0%/year,𝑃 = 0.03) and in 5–9-year-old persons (7.6%/year,
𝑃 < 0.0001) but not in 10–14- or 15–17-year-old persons [2]
(Table 1).
A recent study by Kappelman et al. was carried out in
North Carolina to determine the prevalence of CD and UC
in a commercially insured US population and to compare
prevalences across sociodemographic and temporal condi-
tions [49]. Data from three consecutive 2-year cross-sectional
studies based on claims data collected from approximately
12 million Americans were analysed. In 2009, the preva-
lences of CD and UC in children were 58/100,000 (95%
confidence interval (CI) 55–60) and 34/100,000 (95% CI 32–
36), respectively. In adults, the respective prevalences were
241/100,000 (95%CI 238–245) and 263/100,000 (95%CI 260–
266). According to data analysis, IBDprevalences had slightly
increased over time. Based on census data, estimated 1,171,000
Americans have IBD (565,000 CD and 593,000 UC). The
authors concluded that the burden of IBDhas been increasing
in the US over recent years [49] (Table 1).
A study by Kugathasan et al. [14] aimed to define
epidemiologic and clinical characteristics of newly diagnosed
paediatric IBD patients in a large population-based model
in Winsconsin. All paediatric gastroenterologists providing
care for Winsconsin children voluntarily identified all new
cases of IBD during a 2-year period. The incidence of IBD
in children living in that state was 7.05 per 100,000, and
the incidence for CD was 4.56, more than twice that of UC
(2.14). The IBD incidence rate was found to be similar in the
different ethnic groups as well as in the sparsely as opposed to
densely populated counties. The majority (89%) of new IBD
diagnoses were nonfamilial [14] (Table 1).
Basu et al. [15] conducted a survey on 148 IBD patients
attending a university gastroenterology clinic in Houston,
Texas, between June 1999 and November 2003 to analyse
and compare the impact of IBD on the quality of life in
the various ethnic groups living in the United States. Whites
made up 40%, African Americans 37%, Mexican Americans
20%, and Asians 3% of the total IBD population. African
Americans andwhites predominantly hadCD,whileMexican
Americans predominantly had UC. There was no difference
between African Americans and Mexican Americans when
separately compared to whites in terms of intestinal mani-
festations of CD and UC. African Americans with CD had
a significantly higher incidence of IBD-associated arthritis
(𝑃 = 0.004) and ophthalmological manifestations, notably
uveitis (𝑃 = 0.028), compared to whites. White UC patients
had significantly higher incidences of joint symptoms (𝑃 <
0.0001) and osteoporosis (𝑃 = 0.001) with respect to
MexicanAmericanUCpatients.Whites had a stronger family
history of IBD and colorectal carcinoma compared to the
other ethnic groups. The authors concluded that there are
significant differences in IBD subtypes and serologic markers
in the different racial/ethnic groups living in theUnited States
[15] (Table 1).
Hispanics are the fastest growing minority in the US.
A recent retrospective study [50] aimed to compare IBD
presentation in Hispanic and non-Hispanic whites (NHWs)
and in US-born and foreign-born Hispanics. The fact that
differences in IBD presentation were found in NHW, US-
born Hispanic, and foreign-born Hispanic groups in this
study underlines the importance of environmental factors in
the disease’s development. A total of 325 adult patients were
included, 208 of whom were Hispanics. The foreign-born
Hispanics, accounting for 68% of the total, were diagnosed at
an older age than the US-born Hispanics and the NHWs (45
versus 25 and 27, resp.,𝑃 < 0.05).The foreign-bornHispanics
manifested more UC than the US-born Hispanics or NHWs
(59.9% versus 41% and 28.2%, resp., 𝑃 < 0.05). No difference
was noted in the prevalence of extraintestinal manifestations
between the Hispanics and NHWs. More cases of upper
gastrointestinal tract CD were found in the NHWs (12.5%
versus 3.9%, 𝑃 < 0.05). The rate of IBD-related surgical
procedures was higher in the NHWs than in the Hispanics
(22.9 versus 7.3 surgeries/100 person-years, 𝑃 < 0.01). The
Hispanic patients had fewer prescriptions for biologics and
immunomodulators with respect to the NHWs (22.2% versus
55.6%, 𝑃 < 0.01, and 35.7% versus 53.8%, 𝑃 < 0.01, resp.)
[50].
In two recent retrospectivemulticenter studies conducted
in Argentina and Brazil on cohorts of paediatric patients
(𝑁 = 424) diagnosed with IBD between 1988 and 2007, the
proportion of UC and CD was 62% and 24%, respectively, in
Argentina, and 52% and 48%, respectively, in Brazil. Age at
diagnosis (𝑃 = 0.076) was similar in the UC (9.1; 4.6–12.0)
and CD patients (9.6; 6.9–13.7) [51].
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Pancolitis was the most frequent UC localisation both in
Argentina (77%) and in Brazil (76%). Ileocolonic CD local-
isation was predominant both in the Argentine (46%) and
Brazilian (37%) population. The most common phenotype
of CD (77%) in the Argentine children was inflammatory.
Penetrating CD was predominant in the Brazilian children
(27%) [51].
3.5. Asia. The epidemiologic and clinical characteristics of
IBD patients were assessed by Tozun et al. [16] in a large
multicenter, countrywide hospital-based study in Turkey.
Twelve centers distributed throughout the country registered
all new IBD cases diagnosed between 2001 and 2003. The
incidence in the referral population during the study period
was 4.4/100,000 for UC and 2.2/100,000 for CD. The IBD
incidence in Turkey was lower than that in North and West
Europe and similar to that in theMiddle East.Themajority of
the IBD cases were diagnosed in young adults (20 to 40 yrs).
A characteristic biphasic age distribution was found with
one peak between 20 and 30 and another between 50 and
70. Male predominance was noted in both diseases. Family
history was positive in 4.4% in the UC and 8.3% in the CD
patients. Extraintestinal manifestations were more frequent
in the CD patients, with the exception of arthritis which was
equally frequent in both the CD and UC patients. The rate of
extraintestinalmanifestationswas lower than that reported in
the literature [16] (Table 1).
Abdul-Baki et al. [17] found an age-adjusted prevalence of
53.1 per 100,000 persons forCDand 106.2 per 100,000 persons
for UC in a representative Lebanese cohort.Themean annual
incidence was 4.1 per 100,000 persons for UC and 1.4 per
100,000 persons for CD (range, 0–6.9/100,000 for both). The
prevalence of IBD of this cohort fell in the intermediate range
of that reported for white populations in Europe and North
America.Themean age at diagnosis for patients with CD and
UC was 28.8 ± 11.1 and 32.0 ± 13.4 years, respectively, and a
slight female predominance was noted in the patients studied
[17] (Table 1).
El Mouzan et al. [18] assessed the medical records of
patients in Saudi Arabia younger than 18 whowere diagnosed
with IBD andmonitored over a 10-year period. Fifty consecu-
tive childrenwere diagnosedwith IBDbetween 1993 and 2002
resulting in an estimated incidence of 0.5 cases/100,000/year
and prevalence of 5 cases/100,000 persons in the Riyadh
region of Saudi Arabia.Most of the children (90%)were Saudi
nationals and the female to male ratio was 1 : 0.6. Sixteen
percent of the patients in the 5–18-year-old age bracket were
younger than 12. Chronic UC was the most common form
accounting for 48%, followed by CD and IBD-U in 38%
and 16%, respectively. Although the incidence and prevalence
of IBD in this report were lower than those in any other
population, a comparison with data collected previously
indicates that the incidence is increasing [18] (Table 1).
Together with urbanization and socioeconomic develop-
ment, the incidence of IBD is increasing in China. A prospec-
tive, population-based incidence study was conducted by
Zeng et al. [13] between July 2011 and June 2012 in Zhongshan,
Guangdong, China. All newly diagnosed IBD cases in that
region were included. Forty-eight new cases of IBD (17 CD
and 31 UC) were identified over the 1-year study period.
Age-standardized incidence rates for IBD, UC, and CD were
3.14, 2.05, and 1.09 per 100,000, respectively. Median ages at
diagnosis were 38 for UC and 25 for CD. Disease localisation
in the CD patients was defined as terminal ileum only (L1) in
24% of the cases, isolated colonic disease (L2) in 6% of the
patients, and ileocolonic disease (L3) in 71% of the patients.
Twenty-four percent of the CD patients had coexisting upper
gastrointestinal (GI) involvement (L4) [30]. Inflammatory
(B1), stricturing (B2), and penetrating (B3) behaviour was
noted in 65%, 24%, and 12% of the CD patients, respectively.
Fifty-nine percent of the CD and 26% of the UC patients had
extraintestinal manifestations [13] (Table 1).
Another prospective study conducted between January
and December 2010 by Zhao et al. [52] investigated the inci-
dence of IBD in Wuhan, a major city in central China, using
population-basedmethods. New IBD cases were identified in
17 central hospitals providing health care services in central
Wuhan. Overall, 131 new cases of IBD were identified during
the 1-year period, including 97 cases of UC and 34 cases of
CD. The age-adjusted incidence of IBD, UC, and CD was
1.96 per 100,000 (range 1.62–2.30 per 100,000), 1.45 (range
1.16–1.75), and 0.51 (range 0.33–0.68), respectively. Disease
was localized in the small bowel only (L1) in 15% of the CD
patients, in isolated colonic disease (L2) in 24%, and in the
ileo-colon (L3) in 61%. CD phenotypes were inflammatory in
44% of the cases, stricturing in 29%, and penetrating in 24%.
In the UC patients 34.5% had proctitis, 44.6% had left-sided
colitis, and 19.5% had extensive colitis [52].
According to the two latter studies, the incidence of IBD
in China is similar to that in Japan and Hong Kong but
lower than that in South Korea and countries of the Western
Hemisphere [13, 52].
The Asia-Pacific Crohn’s and Colitis Epidemiology Study,
a large-scale population-based study, reported that although
the incidence of IBD varies throughout Asia, it is still lower
than that in the West. IBD can nevertheless be as severe
or even more severe in Asia than it is in the West [20].
China has the highest incidence of IBD in Asia (3.44 per
100,000 individuals). The UC/CD ratio was 2.0 in Asia and
0.5 inAustralia. ComplicatedCD (stricturing, penetrating, or
perianal disease) wasmore common in Asia than in Australia
(52% versus 24%; 𝑃 = 0.001), and a family history of IBD was
less common in Asia (3% versus 17%; 𝑃 < 0.001) (Table 1).
A study conducted by Tsai et al. aimed to delineate the
trend in incidence and clinical patterns of childhood IBD in
Taiwan [19]. All children admitted to the National Taiwan
UniversityHospital (NTUH) between 1979 and 2000meeting
the criteria for IBD were included. The clinical features and
outcomes were analysed retrospectively. Seventeen children
(9 females and 8 males, aged 2 months to 18 years) were
diagnosed with IBD during the study period. Six (35%) of
these had UC and 9 (53%) CD. The cumulative incidence
of CD during 1979–1995 was 0.85% and increased to 2.6%
during 1996–2000 (𝑃 < 0.001), while the incidence of UC
did not change significantly between the two periods (from
0.85% to 0.99%, 𝑃 = 0.16). The median interval from onset
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to diagnosis was 7.7 months. Eighty percent of the patients
showed moderate to severe disease activity at diagnosis [19].
Pinsk et al. [21] conducted a study which aimed to
determine the incidence of IBD and disease subtype in the
SouthAsian paediatric population living in BritishColumbia,
Canada, compared with non-South Asian IBD patients living
in the same area. A chart review was carried out with data
collected for all patients ≤16 yr of age diagnosed with IBD
from January 1985 to June 2005. Seventy-five South Asian
patients were diagnosed with IBD, 48% with CD, 33.3% with
UC, and 18.7% with IBD-U, as opposed to 71%, 18.8%, and
10.2%, respectively, in the non-South Asian population. The
incidence rate for South Asian IBD patients for the 1996–
2001 period was 15.19/10 (6.41/10 for CD, 6.70/10 for UC,
and 2.08/10 for IBD-U) compared with 5.19/10 for the non-
South Asian IBD group (3.69/10, 0.96/10, and 0.54/10, resp.).
The South Asian male/female ratio was significantly different
from that observed for the rest of the population. According
to these data, there was a significantly higher incidence of
IBD in the South Asian paediatric population compared with
the rest of the BC paediatric population, as well as a different
pattern of phenotypic expression, a male predominance, and
more extensive colonic disease.Migration and environmental
and lifestyle changes seem on the basis of these results to have
an effect on the incidence of IBD and disease subtype [21]
(Table 1).
4. The Natural History of Paediatric IBD
4.1. The Natural History of Crohn’s Disease. Although the
natural history of paediatric CD is characteristically unpre-
dictable [53], the following factors are fundamental in deter-
mining disease evolution [54]: disease activity, the rate of
recurrence and complications over time, the need for surgery,
and its impact on quality of life.
In terms of growth impairment, approximately 50% of
adults with CD presenting in developmental age reach a final
height that is 10% lower than that in the general population,
and in 25% of cases 5% lower than the established target [55].
Representing an important consideration in 28–36% of
cases after the first year of treatment, the risk of corticosteroid
dependency is similar in adults and children, regardless of
concomitant administration of immunosuppressants. While
the use of corticosteroids is efficacious in treating an acute
phase of IBD, prolonged use should be avoided or limited
[55].
Intestinal surgery is required in as high as 80% of CD
patients, and a permanent stoma is required in more than
10% [27].The risk is higher in patients with genotype NOD2-
CARD15 and fibrostenosing disease and in those with serum
positivity for anti-ASCA antibodies [55].
Postsurgical relapses occur in 20–30% of adult CD
patients, and they are endoscopically documented in 43–
79% of cases. In children, the global recurrence rate after 5
years is estimated at 50% and varies, depending on disease
localization [53].
Patients with CD have higher mortality rates with respect
to the general population [44]. Only precocious aggressive
therapeutic strategies focusing on treating early recurrent
lesions in asymptomatic individuals seem to have a significant
impact on progression of this chronic disease [44].
Four hundred and four CD children (<17 years at diagno-
sis) forming a geographically derived incidence cohort were
diagnosed between 1988 and 2002, by Vernier-Massouille et
al. [54] andmonitored for approximately two years.Themost
frequent disease location at diagnosis was the terminal ileum-
colon (63%). Disease progression was noted in 31% of the
children during the followup. Complicated behaviour was
observed in 29% of the children at diagnosis and 59% at
followup. Kaplan-Meier survival estimates of the cumulative
incidence of surgery were 20% at 3 years and 34% at 5
years after diagnosis. Multivariate Cox models showed that
both stricturing behaviour at diagnosis and treatment with
corticosteroids were associated with an increased risk for
surgery, while treatment with azathioprine was associated
with a decreased one. Azathioprine was introduced earlier in
the course of disease in patients not undergoing surgery than
in those patients requiring surgery. The authors concluded
that paediatric CDwas characterized by frequent recurrences
and severe complicated disease behaviour. Immunosuppres-
sive therapy seemed to improve the natural history of the
disease and to reduce the need for surgery [54].
4.2.TheNatural History of Ulcerative Colitis. Both the clinical
presentation at the time of diagnosis and the disease course of
UC are heterogeneous and variable over time, and colectomy
is one of its major risks [56].
The clinical characteristics of UC that influence its course
include the extent and the severity of the disease at diagnosis,
both of which correlate with a higher rate of colectomy
[56]. While colectomy is required in approximately 10%–
30% of UC patients [57], mortality in these patients has not
been found to be higher with respect to that in the general
population [57].
Just as in adult patients, the response to corticosteroid
therapy plays an important role in defining the natural history
of the disease in the paediatric population [56].
A short-term remission has been found in 75–80% of
children and a long-term one in 60% of patients according
to a recent report on the efficacy of biological drugs in UC
patients [56, 57].
Gower-Rousseau et al. [58] identified 113 UC children
(<17 years at diagnosis) in a geographically derived incidence
cohort between 1988 and 2002 who were monitored for at
least 2 years. At diagnosis, 28% of the patients had proctitis,
35% left-sided colitis, and 37% extensive colitis. Forty-nine
percent of the patients showed disease progression. A delay
in diagnosis longer than 6 months and a family history
of Inflammatory Bowel Disease were associated with an
increased risk of disease progression. The cumulative rate
of colectomy was 8% at 1 year, 15% at 3 years, and 20% at
5 years following diagnosis. The presence of extraintestinal
manifestations at diagnosis was associated with an increased
risk of colectomy. In the patients with limited disease at
diagnosis, the risk of colectomy was higher in those who
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experienced disease progression with respect to those who
did not [58].
5. Discussion
IBDs are an example of pathological entities having a mul-
tifactorial etiology. Over the past several decades, advances
have been made in understanding the epidemiology of IBD.
At the same time, the incidence and prevalence of both CD
and UC have been increasing worldwide across pediatric and
adult populations and its epidemiology is evolving. It is to
be remembered, however, that the rising pattern may also
be due to advances in disease detection and recognition and
continued environmental alterations and exposures impact-
ing disease onset. At the same time, the disease is emerging in
previously low prevalence areas such as the developing world
and among emigrant populations moving to industrialized
Westernized societies. Genetic mutations that have been
detected can explain a number (about 20–30%) of diagnosed
cases but the evidence of IBD’s rising frequency in indus-
trialized areas of the world also implicates environmental
risk factors [1, 29, 30]. The geographical variability in IBD
incidence and prevalence may, in turn, reflect a variety of
underlying genetic patterns in different populations [31]. As
IBD’s prevalence and incidence vary among different ethnic
groups and the disease’s clinical spectrum is still evolving,
environmental factors may continue to contribute to its
pathogenesis. Industrialization and globalisation seem, in any
case, to be associated with the disease’s spreading, rising
pattern. In view of these considerations, a growing number
of gastroenterologists and paediatricians have become inter-
ested in the disease’s underlying epigenetic mechanisms.
Some gastroenterologists are particularly concerned
about exposure to antibiotics in childhood and specific diets
such as the “Western” one containing processed, fried, and
sugary foods or low in omega-3 fatty acids may be linked
to IBD presentation and the common mechanism may be
through an alteration of the gut flora [30]. Greater discretion
in prescribing antibiotics to children and ensuring that diets
are high in omega-3 fatty acids may be appropriate measures
especially in high risk families (positive family history for
IBD). Future strategies may aim to modulate gut flora either
with antibiotics targeting identified noxiousmicrobes or with
selective probiotics that can rebalance the gut dysbiosis [30].
Until now study findings have primarily been retrospec-
tive and subject to recall bias and for the most part they have
been carried out in richer countries that have the means to
do so. As IBD is a relatively rare disorder, with complicated
interactions between potential inciting agents, very large
cohorts with detailed, prospectively collected, environmental
exposure data are needed. At the same time large, well-
phenotyped cohorts of IBD patients are likewise necessary
if we are to study the effects of environmental exposures on
disease course.
In view of these considerations and in particular of the
disease’s ever evolving epidemiology and impact on quality
of life, epidemiologic data must be gathered and analyzed
following a systematic, rigorous process. As demonstrated in
this review, the process of diagnosing and enrolling patients,
be they adults or children, is a complex endeavor. Incidence
and prevalence figures extrapolated from published studies
regarding paediatric patients have, in particular, been found
to be extremely heterogeneous. Establishing multicenter
national and international registers and networks would be
a step forward in the direction of constructing a shared
database system utilizing an established, homogeneous cri-
teria.
This review has attempted to examine the quality of
epidemiologic data found in the principal studies carried out
on the general and paediatric populations and to identify
the weaknesses and gaps existing in the information that is
presently available. Implementing a shared database system
will hopefully lead the way to well-designed studies and to
new, important treatment breakthroughs.
6. Conclusions
The highest incidence rates of IBD are in Europe and
North America, although the overall prevalence of both CD
and UC is increasing throughout the world. Assessing the
incidence of IBD is, nevertheless, complicated, especially in
the developmental age.
Geographical variability in IBD incidence and prevalence
might reflect different underlying genetic patterns within
different populations. As there are important differences in
the prevalence of IBD between different racial and ethnic
groups it is possible that the disease’s clinical spectrum is still
evolving and that environmental factors might be involved
in its pathogenesis. Industrialization and globalization seem
nevertheless to be associated with a spreading increasing
incidence of IBD.
IBD has a significant impact on patients’ quality of life
and is generally associated with a high financial burden due
to elevated medical costs in particular with regard to biologic
drugs.
An analysis of data emerging from multicenter national
registers and international networking can provide informa-
tion on IBD epidemiology and lead to hypothesis about its
causes and possible management strategies.
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